Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 January 2020Website:
http://www.arcutis.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:17:46 GMTDividend
Analysts recommendations
Institutional Ownership
ARQT Latest News
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United States, expanding ZORYVE portfolio availability to over 2 million Canadians living with seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types.
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.
Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Securities Serge Belanger - Needham Chris Shibutani - Goldman Sachs Operator Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call.
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.16 per share a year ago.
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practices Provides access to a large portion of the 7.4 million individuals treated for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis outside of dermatology offices ZORYVE will be promoted in the primary position to maximize prescriber education WESTLAKE VILLAGE, Calif. and MONTGOMERY, Ala.
Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be used anywhere on the body for any duration to maintain clear skin Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States Management will host an investor event with a key opinion leader on Monday, July 29 at 8:30 am EDT/5:30 am PDT WESTLAKE VILLAGE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United States.
What type of business is Arcutis Biotherapeutics?
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for dermatological diseases. The company was previously known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Our company is headquartered in Westlake Village, California. The company has a broad portfolio of drugs with significant potential for treating immune-mediated dermatological diseases and conditions. The company's lead product candidate is ARQ-151, a cream with roflumilast for the treatment of plaque psoriasis. The company is also developing ARQ-154, a roflumilast foam formulation for topical use to treat seborrheic dermatitis and scalp psoriasis. ARQ-252, a selective topical Janus kinase type 1 inhibitor for the treatment of chronic hand eczema and vitiligo. ARQ-255, a local formulation of ARQ-252, developed for deeper penetration into the skin to treat focal alopecia.
What sector is Arcutis Biotherapeutics in?
Arcutis Biotherapeutics is in the Healthcare sector
What industry is Arcutis Biotherapeutics in?
Arcutis Biotherapeutics is in the Biotechnology industry
What country is Arcutis Biotherapeutics from?
Arcutis Biotherapeutics is headquartered in United States
When did Arcutis Biotherapeutics go public?
Arcutis Biotherapeutics initial public offering (IPO) was on 31 January 2020
What is Arcutis Biotherapeutics website?
https://www.arcutis.com
Is Arcutis Biotherapeutics in the S&P 500?
No, Arcutis Biotherapeutics is not included in the S&P 500 index
Is Arcutis Biotherapeutics in the NASDAQ 100?
No, Arcutis Biotherapeutics is not included in the NASDAQ 100 index
Is Arcutis Biotherapeutics in the Dow Jones?
No, Arcutis Biotherapeutics is not included in the Dow Jones index
When was Arcutis Biotherapeutics the previous earnings report?
No data
When does Arcutis Biotherapeutics earnings report?
The next expected earnings date for Arcutis Biotherapeutics is 06 November 2024